BerGenBio Provides Interim Update on Phase II Clinical Programme With Selective Oral AXL Inhibitor Bemcentinib
Summary
Richard Godfrey, BerGenBio CEO, commented: "We are excited to present these very encouraging interim results from our broad Phase II clinical development programme in a variety of tumour types with a significant unmet medical need.In addition, we are making good progress with our studies to identify predictive biomarkers that we anticipate may be developed as companion diagnostics for personalized therapy.BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors as a potential cornerstone of combination cancer therapy.BerGenBios lead product, bemcentinib (BGB324), is a selective, potent and orally bio-available small molecule AXL inhibitor in four Company sponsored Phase II clinical trials in major cancer indications, with read-outs anticipated during 2018.The clinical trials combining bemcentinib with KEYTRUDA in adenocarcinoma of the lung and TNBC are conducted in collaboration with Merck & Co., Inc. (Kenilworth, NJ, USA), through a subsidiary.
Classifications
AskAI Classifications
LabelsLinked Companies
